Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20457066 | 0.85 | LMNA (0.35) | KDM4E | |
| SCHEMBL24967231 | 0.85 | — | — | |
| SCHEMBL27269539 | 0.85 | MEN1 (0.32) | NOS3NOS1NOS2TSHRCCR4 | |
| SCHEMBL12570324 | 0.80 | NOS3 (0.48) | NOS3NOS1NOS2TSHRCCR4 | |
| SCHEMBL21718453 | 0.78 | CCR1 (0.40) | NOS3NOS1NOS2KDM4EATM | |
| SCHEMBL13253381 | 0.76 | CA2 (0.31) | TSHR | |
| SCHEMBL10236287 | 0.74 | NOS3 (0.43) | NOS3NOS1NOS2TSHRCCR4 | |
| SCHEMBL8008974 | 0.74 | TDP1 (0.36) | NOS3NOS1NOS2TSHRCCR4 | |
| SCHEMBL26703718 | 0.74 | GABRA1 (0.34) | NOS3NOS1NOS2TSHRCCR4 | |
| SCHEMBL15429556 | 0.74 | NOS2 (0.54) | NOS3NOS1NOS2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154984-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191437-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-12-17 | — | — | WO | claimed |
| EP-1146887-A4 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | UNIV PRINCETON (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2000041710-A9 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | UNIV PRINCETON (US) | 2001-11-22 | — | — | WO | claimed |
| EP-1146887-A1 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | Princeton University (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000041710-A1 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | claimed |
| US-5403803-A | Polymerization catalyst for alpha-olefins | EXXON CHEMICAL PATENTS INC. (US) | 1995-04-04 | — | — | US | claimed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-115298165-A | Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-1146887-A1 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | Princeton University (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1095058-A1 | GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME | Princeton University (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000069892-A1 | GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME | PRINCETON UNIVERSITY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000041710-A1 | GLYCOPEPTIDE ANTIBIOTICS CONTAINING A DESMETHYLVANCOSAMINE RESIDUE, COMBINATORIAL LIBRARIES OF SAME AND METHODS OF PRODUCING SAME | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000004044-A1 | GLYCOPEPTIDE ANTIBIOTICS, COMBINATORIAL LIBRARIES OF GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF PRODUCING SAME | PRINCETON UNIVERSITY (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1995009190-A1 | CARBOCATIONIC CATALYST AND PROCESS FOR ITS USE | EXXON CHEMICAL PATENTS INC. (US) | 1995-04-06 | — | — | WO | disclosed |
| US-5403803-A | Polymerization catalyst for alpha-olefins | EXXON CHEMICAL PATENTS INC. (US) | 1995-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | NOS3 4665/4885NOS1 4619/4885NOS2 4668/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | NOS3 4013/4885NOS1 4171/4885NOS2 4166/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | NOS3 383/4885NOS1 129/4885NOS2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.